Interferon beta-1b
- Generic Name
- Interferon beta-1b
- Brand Names
- Betaferon, Betaseron, Extavia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145155-23-3
- Unique Ingredient Identifier
- TTD90R31WZ
- Background
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
- Indication
Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
Phase 1
Completed
- Conditions
- HIV InfectionsSarcoma, Kaposi
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 36
- Registration Number
- NCT00000695
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath